{
    "organizations": [],
    "uuid": "8607ca8120e0003e6aee155d389fb71a9424555e",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/08/globe-newswire-neos-therapeutics-to-host-fourth-quarter-and-year-end-2017-financial-results-conference-call-on-march-15-2017.html",
    "ord_in_thread": 0,
    "title": "Neos Therapeutics to Host Fourth Quarter and Year-End 2017 Financial Results Conference Call on March 15, 2017",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "DALLAS and FORT WORTH, Texas, March 08, 2018 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that it will report fourth quarter and year-end 2017 financial results prior to the opening of U.S. financial markets on Thursday, March 15, 2017. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. ET that same day.\nThe live call may be accessed by dialing (877) 388-8985 for domestic calls, or +1 (562) 912-2654 for international callers, and referencing conference ID number 5653457. A live audio webcast for the conference call will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/ .\nAbout Neos Therapeutics\nNeos Therapeutics, Inc. (NASDAQ:NEOS) is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODT ® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), Cotempla XR-ODT™ (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information , including Boxed WARNING), and Adzenys-ER™ (amphetamine) extended-release oral suspension (see Full Prescribing Information , including Boxed WARNING), all for the treatment of ADHD, are the first three approved products using the Company’s extended-release technology platform. Additional information about Neos is available at www.neostx.com .\nContacts:\nRichard Eisenstadt\nChief Financial Officer\nNeos Therapeutics\n(972) 408-1389\nreisenstadt@neostx.com\nSarah McCabe\nSenior Vice President\nStern Investor Relations, Inc.\n(212) 362-1200\nsarah@sternir.com\nSource:Neos Therapeutics, Inc.",
    "published": "2018-03-08T15:30:00.000+02:00",
    "crawled": "2018-03-08T16:24:26.022+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "dallas",
        "fort",
        "worth",
        "texas",
        "march",
        "globe",
        "newswire",
        "neos",
        "therapeutic",
        "nasdaq",
        "neos",
        "pharmaceutical",
        "company",
        "focused",
        "developing",
        "manufacturing",
        "commercializing",
        "innovative",
        "xr",
        "product",
        "using",
        "proprietary",
        "drug",
        "delivery",
        "orally",
        "disintegrating",
        "tablet",
        "odt",
        "technology",
        "platform",
        "today",
        "announced",
        "report",
        "fourth",
        "quarter",
        "financial",
        "result",
        "prior",
        "opening",
        "financial",
        "market",
        "thursday",
        "march",
        "neos",
        "management",
        "host",
        "conference",
        "call",
        "live",
        "audio",
        "webcast",
        "discus",
        "result",
        "provide",
        "company",
        "update",
        "et",
        "day",
        "live",
        "call",
        "may",
        "accessed",
        "dialing",
        "domestic",
        "call",
        "international",
        "caller",
        "referencing",
        "conference",
        "id",
        "number",
        "live",
        "audio",
        "webcast",
        "conference",
        "call",
        "available",
        "investor",
        "relation",
        "page",
        "company",
        "website",
        "http",
        "neos",
        "therapeutic",
        "neos",
        "therapeutic",
        "nasdaq",
        "neos",
        "pharmaceutical",
        "company",
        "focused",
        "developing",
        "manufacturing",
        "commercializing",
        "product",
        "utilizing",
        "proprietary",
        "drug",
        "delivery",
        "technology",
        "platform",
        "adzenys",
        "amphetamine",
        "orally",
        "disintegrating",
        "tablet",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "cotempla",
        "methylphenidate",
        "orally",
        "disintegrating",
        "tablet",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "amphetamine",
        "oral",
        "suspension",
        "see",
        "full",
        "prescribing",
        "information",
        "including",
        "boxed",
        "warning",
        "treatment",
        "adhd",
        "first",
        "three",
        "approved",
        "product",
        "using",
        "company",
        "technology",
        "platform",
        "additional",
        "information",
        "neos",
        "available",
        "contact",
        "richard",
        "eisenstadt",
        "chief",
        "financial",
        "officer",
        "neos",
        "therapeutic",
        "reisenstadt",
        "sarah",
        "mccabe",
        "senior",
        "vice",
        "president",
        "stern",
        "investor",
        "relation",
        "sarah",
        "source",
        "neos",
        "therapeutic",
        "inc"
    ]
}